Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration-论文-万方医学网

首页> > Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

导出原文传递

翻译打印收藏纠错

第一作者： Molto, Consolacion

作者： Molto, Consolacion ^[1] ; Hwang, Thomas J. ^[2] ; Borrell, Maria ^[3] ; Andres, Marta ^[4] ; Gich, Ignasi ; Barnadas, Agusti ; Amir, Eitan ; Kesselheim, Aaron S. ; Tibau, Ariadna

作者单位： Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Inst Invest Biomed St Pau, Oncol Dept, Carrer St ^[1] Brigham & Womens Hosp, Prog Ram Regulat Therapeut & Law, 75 Francis St, Boston, MA 02115 USA ^[2] Hosp Santa Creu & Sant Pau, Dept Epidemiol, Barcelona, Spain ^[3] Princess Margaret Canc Ctr, Dept Med, Div Med Oncol & Hematol, Toronto, ON, Canada ^[4]

关键词 American Society of Clinical Oncology (ASCO)breakthrough therapy designation clinical benefit cost European Society for Medical Oncology (ESMO)value frameworks

发布时间 2022-09-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

相似文献

中文期刊
外文期刊
学位论文
会议论文

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

法律状态公告日	法律状态	法律状态信息

检索历史清除

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

相似文献

同项目论文

相关期刊

检索历史 清除

Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration

相似文献

同项目论文

相关期刊

检索历史清除